Occult Malignancy Must Be Actively Pursued in This TMA Case
When infection, autoimmune disease, drugs, and hereditary causes have been ruled out in a patient with TMA and no history is available, occult malignancy becomes a critical diagnostic consideration that requires immediate and systematic investigation.
Why Malignancy Is a Priority Consideration
According to the most recent 2025 guidelines, malignancy accounts for approximately 19% of secondary TMA cases 1. In a large retrospective study of 564 TMA patients, only 6% had primary TMA (TTP or atypical HUS), while 94% had secondary causes—with malignancies representing a substantial proportion 1, 2. This makes cancer-associated TMA far more common than many clinicians realize.
The pathophysiology involves direct endothelial injury from tumor cells, paraneoplastic mechanisms, or chemotherapy-induced toxicity 3. Cancer-related TMA carries particularly poor outcomes compared to other secondary causes 4, making early detection crucial for mortality reduction.
Systematic Approach to Detecting Occult Malignancy
Immediate Laboratory Screening
- Lactate dehydrogenase (LDH): Persistently elevated beyond what hemolysis alone explains
- Tumor markers: CA 19-9, CEA, CA-125, PSA (age/sex appropriate)
- Complete metabolic panel: Look for hypercalcemia, elevated alkaline phosphatase suggesting bone metastases
Imaging Protocol
- CT chest/abdomen/pelvis with contrast as first-line comprehensive screening
- PET-CT scan if initial CT is unrevealing but clinical suspicion remains high 5
- Bone marrow biopsy if pancytopenia or unexplained constitutional symptoms present
Specific Cancer Types to Consider
The most common malignancies causing TMA include:
- Adenocarcinomas (gastric, pancreatic, breast, lung, prostate) - most frequent
- Rectal/colorectal cancer 5
- Metastatic disease is often present at TMA diagnosis 3, 5
Critical Diagnostic Pitfall
Do not assume TMA improvement with plasma exchange rules out malignancy. Case reports demonstrate that patients may show temporary hematological improvement with supportive care, only to have underlying cancer discovered later 5. In one case, a patient achieved complete hematological recovery after plasma exchange, but persistent LDH elevation and new bone pain led to the discovery of metastatic rectal cancer 5.
Treatment Implications While Investigating
While pursuing malignancy workup:
- Continue plasma exchange and supportive care as temporizing measures 1
- Consider complement inhibition (eculizumab) in select cases, particularly if genetic testing reveals complement abnormalities even in the setting of suspected secondary TMA 6, 3
- Perform ADAMTS13 testing to definitively exclude TTP, but remember that moderately reduced ADAMTS13 (10-50%) can occur with malignancy-associated TMA 1
Genetic Testing Is Still Warranted
Even when secondary causes like malignancy are suspected, genetic complement testing should be performed 6. Recent data shows that 60% of patients with complement-related mutations showed improvement with complement inhibition at 6 months, even when secondary triggers were present 6. Many "secondary" TMAs may harbor unrecognized complement abnormalities that make them responsive to targeted therapy.
Prognosis Considerations
Malignancy-associated TMA has among the worst outcomes of all TMA etiologies 4. Mortality rates are significantly higher than infection or drug-induced TMA. The presence of metastatic disease at presentation further worsens prognosis 3, 5. This underscores why aggressive investigation cannot be delayed—early cancer detection may be the only opportunity to improve survival.